About 3,938 results

ALLMedicine™ Astrocytoma Center

Research & Reviews  1,423 results

Human astrocytes and astrocytoma respond differently to resveratrol.
Nanomedicine : Nanotechnology, Biology, and Medicine; Gran ER, Lotocki V et. al.

Jul 24th, 2021 - A fundamental problem in oncology is that anticancer chemotherapeutics kill both cancer and healthy cells in the surrounding tissues. Resveratrol is a natural antioxidant with intriguing and opposing biological properties: it reduces viability of ...

Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis ...
https://doi.org/10.1007/s40263-021-00839-4 10.1186/s13023-019-1258-3 10.1590/1678-4685-gmb-2015-0321 10.1038/sj.ejhg.5201402 10.1016/j.purol.2020.05.011 10.1007/s00246-016-1528-y 10.1016/j.pediatrneurol.2017.04.008 10.3928/19382359-20170320-01 10.1111/j.1528-1167.2009.02474.x 10.1016/j.yebeh.2017.02.007 10.1016/j.yebeh.2019.106844 10.2217/pgs.13.143 10.1371/journal.pone.0158476 10.1371/journal.pone.0180939 10.1212/CPJ.0000000000000514 10.1016/j.yebeh.2018.05.039 10.1007/s40272-019-00337-7 10.1016/j.pediatrneurol.2013.08.001 10.1371/journal.pmed.0040296 10.1111/epi.13089 10.1016/j.yebeh.2012.01.021 10.1111/epi.16099 10.1016/j.ejpn.2019.02.014 10.1016/j.yebeh.2004.08.001 10.1016/j.yebeh.2008.02.006 10.3109/07853890109002087 10.1023/A:1008853819715 10.1093/biostatistics/kxw030 10.1093/biostatistics/kxt032 10.1080/02664760220136168 10.1186/s13023-018-0775-9 10.1186/s13023-018-0915-2 10.1056/NEJMoa1100391 10.1016/j.urology.2016.04.027 10.1080/03007995.2017.1313726 10.1542/peds.2010-2910 10.4103/apc.APC_79_18 10.1016/j.ejpn.2018.06.007 10.1001/jamadermatol.2018.0465 10.1016/j.jaad.2015.07.018 10.1111/jdv.14964 10.1146/annurev-genom-083118-015354 10.1016/j.ejpn.2013.06.002 10.1016/S0140-6736(16)31419-2 10.1212/WNL.0b013e3182815428 10.1186/s13023-016-0530-z 10.1016/j.yebeh.2020.107182 10.1186/s13023-019-1077-6 10.1016/j.braindev.2018.07.003 10.1016/j.ejpn.2018.05.006 10.1080/14656566.2020.1803830 10.1586/17512433.2016.1156529 10.1111/epi.13768 10.1080/14656566.2019.1637420 10.3389/fneur.2018.00569 10.1586/17512433.2015.1091303 10.1080/17512433.2018.1421066 10.1007/s00381-013-2170-0 10.2165/11207730-000000000-00000 10.1002/ana.24523 10.1007/s10147-020-01792-w 10.1016/j.jpeds.2017.06.076 10.1017/S1047951118000598 10.1097/MD.0000000000004562 10.1080/20016689.2019.1618661 10.1016/S1470-2045(17)30471-0 10.1186/s13023-017-0581-9 10.1016/j.jpeds.2016.01.027 10.1111/bcp.13067 10.1016/j.ejpn.2018.01.027 10.14581/jer.18012 10.1016/j.transproceed.2010.07.083
CNS Drugs; Willems LM, Rosenow F et. al.

Jul 18th, 2021 - The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying tr...

hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells Whi...
Pathology Oncology Research : POR; Franzese O, Di Francesco AM et. al.

Jul 14th, 2021 - The neurotrophin nerve growth factor (NGF) modulates the growth of human gliomas and is able to induce cell differentiation through the engagement of tropomyosin receptor kinase A (TrkA) receptor, although the role played in controlling glioma sur...

The feasibility and efficacy of short-term visual-motor training in pediatric posterior...
European Journal of Physical and Rehabilitation Medicine; Kasatkin V, Deviaterikova A et. al.

Jul 12th, 2021 - Pediatric posterior fossa tumor (PFT) survivors experience a range of cognitive and motor impairments that require timely rehabilitation of these functions. In Russia, rehabilitation services are only just beginning to be formed; therefore, it is ...

Upfront therapy of aggressive/high-risk low-grade glioma: single institution outcome an...
World Neurosurgery; Anand S, Chatterjee A et. al.

Jul 10th, 2021 - To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG). Medical records of patients defined as aggressive/high-risk LGG based on clinico-rad...

see more →

Guidelines  1 results

The role of initial chemotherapy for the treatment of adults with diffuse low grade gli...
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.

Nov 4th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...

see more →

Drugs  26 results see all →

Clinicaltrials.gov  76 results

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma

Apr 23rd, 2020 - Group A will be composed of newly-diagnosed, elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and RT. Group B will be composed of newly-diagnosed, elderly patien...

Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor

Feb 4th, 2020 - Brain tumors account for nearly 20% of all childhood malignancies. Of these, gliomas represent 50% of all brain tumors in children and young adults. Gliomas are classically divided into two subtypes - low-grade and high-grade. Low-grade gliomas (L...

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

Jan 6th, 2020 - Brain tumors are the first cause of cancer mortality in children and the 3rd cause in young adults. The most frequent brain tumors are gliomas and among them the most common type is astrocytoma. The most malignant astrocytoma is Glioblastoma (GBM)...

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Nov 18th, 2019 - There were an estimated 22,000 new cases of brain cancers in 2015 in the United States, and 15,000 deaths (Howlader et al., 2014). Glioblastoma (WHO IV), and Anaplastic Astrocytoma (WHO III), are the most common brain cancers, respectively, repres...

Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas

Sep 11th, 2019 - OBJECTIVES: Compare the overall survival and time to tumor progression in patients with anaplastic astrocytoma or mixed gliomas treated with radiotherapy combined with temozolomide vs carmustine or lomustine vs temozolomide and carmustine (arm dis...

see more →

News  46 results

Combination Treatment Fails to Improve Survival in Recurrent Glioma

Nov 4th, 2020 - NEW YORK (Reuters Health) - Following tumor resection in patients with recurrent glioblastoma and anaplastic astrocytoma, treatment with vocimagene amiretrorepvec (Toca 511) and with flucytosine (Toca FC) provides no improvement in overall surviva...

Combination Treatment Fails to Improve Survival in Recurrent Glioma

Nov 4th, 2020 - NEW YORK (Reuters Health) - Following tumor resection in patients with recurrent glioblastoma and anaplastic astrocytoma, treatment with vocimagene amiretrorepvec (Toca 511) and with flucytosine (Toca FC) provides no improvement in overall surviva...

VHA Practice Guideline Recommendations for Diffuse Gliomas

Aug 2nd, 2019 - Case Presentations Case 1. A veteran of the Gulf War presented with a 3-month history of possible narcoleptic events associated with a motor vehicle accident.

A 20-Year-Old Woman With Nail Abnormalities and Vomiting

Jun 5th, 2019 - Discussion This patient was diagnosed with tuberous sclerosis (TS) with renal angiomyolipomas. Also referred to as "tuberous sclerosis complex," TS is an inherited (autosomal dominant) neurocutaneous disorder. It was first described in 1880 by Bou...

Shift Work & Breast Cancer; 'Mind-Boggling' Response; TMB Groupthink?

May 29th, 2019 - Contradicting past research, a new study from the U.K. found no association between working nights and increased breast cancer risk. (British Journal of Cancer) Officials at the FDA are calling for patient-friendly terminology for oncology trial e...

see more →

Patient Education  3 results see all →